StemSight | Curing Blindness With Stem Cells

Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness.

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022

Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023

About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.
READ MORE

Latest News

2026-03-04 00:00:00

StemSight at Sachs European Life Sciences CEO Forum

StemSight attends the 19th Annual European Life Sciences CEO Forum on March 4-5 in Zurich. Our CEO Laura Koivusalo will take the stage on Day 2 of the event.

2025-09-25 00:00:00

StemSight welcomes Charlotta Backman as Head of Clinical Development

We are excited to welcome Charlotta Backman to StemSight as Head of Clinical Development. Charlotta brings her broad expertise on clinical development at the time when StemSight starts preparing for its transition from the pre-clinical setting to the clinic.

2026-02-19 00:00:00

StemSight participates in Japan Entry Acceleration Program (JEAP)

StemSight is selected for competitive Japan Entry Acceleration Program (JEAP) introducing global high-potential biomedical startups to Japan. Read the full press release here.

2025-12-04 00:00:00

StemSight speaking at the ISSCR 2025 PSC-Derived Cell Therapies Symposium in Boston

Our CSO Tanja Ilmarinen will be in Boston on December 11-12 at the International Society for Stem Cell Research Symposium on Pluripotent Stem Cell Therapies. Tanja will be sharing our latest developments from our lead asset STE-101, an off-the-shelf iPS cell derived therapy aimed to cure Limbal Stem Cell Deficiency.

We are excited to be invited as part of this esteemed program featuring pioneers of the industry! For the star line-up, see the program here.

More News

Latest blog post

StemSight Welcomes Charlotta Backman as Head of Clinical Development

Want to know more?

Interested to join our next investment round? Want to hear about our latest developments? Just thought of someone we absolutely need to meet?

Send us a message!

Subscribe to our newsletter

Subscribe now